Preoperative Glucagon-Like Peptide-1 Receptor Agonist Utilization and Association with Bariatric Surgery Outcomes.
AbuHasan Q, Funk LM, Holl JL, Draucker C, Grannis S, Bilimoria KY, Stefanidis D, Yuce TK
Obes Surg 2025 Feb; 35(2): 556-560
[PubMed ID: 39810030]Using Machine Learning to Predict Weight Gain in Adults: an Observational Analysis From the All of Us Research Program.
Jawara D, Lauer KV, Venkatesh M, Stalter LN, Hanlon B, Churpek MM, Funk LM
J Surg Res 2024 Dec 31; 306: 43-53
[PubMed ID: 39742657]U.S. weight trends: a longitudinal analysis of an NIH-partnered dataset.
Jawara D, Krebsbach CM, Venkatesh M, Murtha JA, Hanlon BM, Lauer KV, Stalter LN, Funk LM
Int J Obes (Lond) 2025 Feb; 49(2): 315-321
[PubMed ID: 39472690]Patients experience with preoperative use of anti-obesity medications and associations with bariatric surgery expectations.
Samuels JM, Patel MB, Roumie CL, Self W, Funk L, Spann MD, Niswender KD
Surg Obes Relat Dis 2025 Feb; 21(2): 109-114
[PubMed ID: 39389849]Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery.
Samuels JM, Niswender KD, Roumie CL, Spann MD, Flynn CR, Ye F, Blankush J, Irlmeier R, Funk LM, Patel MB
Diabetes Obes Metab 2024 Sep; 26(9): 3906-3913
[PubMed ID: 38934217]
